{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17", "items" : [{"_about" : "http://data.parliament.uk/resources/997124", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/997124/answer", "answerText" : {"_value" : "

Public Health England (PHE) raises public awareness of the impacts of indoor air pollution by supporting activities that aim to change behaviour, such as the annual Clean Air Day, and is working with health partners, such as the National Institute for Health and Care Excellence, World Health Organization and Allergy UK, to improve the evidence on the health impacts of poor indoor air quality which will enhance advice to the public. PHE also promotes awareness about carbon monoxide through the use of blog posts, press releases and social media updates.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-06T16:28:25.487Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Housing: Health"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to promote public awareness of the the effect on people's health of poor quality indoor environments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "184965"} , {"_about" : "http://data.parliament.uk/resources/1008449", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1008449/answer", "answerText" : {"_value" : "

The total value of the properties owned and managed by NHS Property Services was £3.933 billion at 31 March 2018. This figure is from the 2017/18 annual report and accounts.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2018-11-26", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-26T16:05:49.847Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS Property Services: Buildings"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the total value of the properties managed by NHS Property Services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/338", "label" : {"_value" : "Biography information for Keith Vaz"} } , "tablingMemberConstituency" : {"_value" : "Leicester East"} , "tablingMemberPrinted" : [{"_value" : "Keith Vaz"} ], "uin" : "192093"} , {"_about" : "http://data.parliament.uk/resources/1008450", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1008450/answer", "answerText" : {"_value" : "

The complaints handling process is under constant review. The most significant recent change was in July 2017 with the introduction of a new national customer support centre to provide a clear route into the organisation for customers to raise requests, incidents and complaints.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2018-11-26", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-26T16:04:52.143Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS Property Services: Complaints"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the procedure for dealing with complaints to NHS Property Services was last changed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/338", "label" : {"_value" : "Biography information for Keith Vaz"} } , "tablingMemberConstituency" : {"_value" : "Leicester East"} , "tablingMemberPrinted" : [{"_value" : "Keith Vaz"} ], "uin" : "192094"} , {"_about" : "http://data.parliament.uk/resources/1008457", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1008457/answer", "answerText" : {"_value" : "

Until we can be certain of the outcome of Brexit negotiations our duty as a responsible government is to prepare for all eventualities, including \u2018no deal\u2019. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks\u2019 additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.<\/p>

<\/p>

Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.<\/p>

<\/p>

We understand that statins are vitally important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T15:21:08.397Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Statins"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the supply of statins after the UK leaves the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4573", "label" : {"_value" : "Biography information for Dr Rosena Allin-Khan"} } , "tablingMemberConstituency" : {"_value" : "Tooting"} , "tablingMemberPrinted" : [{"_value" : "Dr Rosena Allin-Khan"} ], "uin" : "192116"} , {"_about" : "http://data.parliament.uk/resources/1008477", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1008477/answer", "answerText" : {"_value" : "

In summer 2018, Public Health England and the Local Government Association published a guide for local authorities which provides an overview of gambling-related harms and how councils can begin to try to help local residents who are impacted by it. It provides information on the current framework for prevention and support, information on the regulatory tools councils can use to help tackle gambling-related harm and the role of public health.<\/p>

<\/p>

\u2018Tackling Gambling Related Harm: A whole council approach\u2019 is available to view at the following link:<\/p>

<\/p>

https://www.local.gov.uk/sites/default/files/documents/10.28%20GUIDANCE%20ON%20PROBLEM%20GAMBLING_07.pdf<\/a><\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-21T14:34:06.687Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Gambling: Rehabilitation"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 November 2018 to Question 186383 on Gambling: Rehabilitation, what steps his Department is taking to ensure that local authorities are able to adequately support people who have gambling addictions.", "registeredInterest" : {"_value" : "true", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4243", "label" : {"_value" : "Biography information for Dan Jarvis"} } , "tablingMemberConstituency" : {"_value" : "Barnsley Central"} , "tablingMemberPrinted" : [{"_value" : "Dan Jarvis"} ], "uin" : "192126"} , {"_about" : "http://data.parliament.uk/resources/1008479", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1008479/answer", "answerText" : {"_value" : "

Following an announcement by NHS England on 14 November 2018, flash glucose monitoring systems will be made available on prescription for all patients with type 1 diabetes who meet National Health Service criteria from April 2019.<\/p>

<\/p>

No estimate has been made of the potential savings related to making flash glucose monitoring technology available to all patients with diabetes.<\/p>

<\/p>

A search of the Department\u2019s Ministerial correspondence database has identified 272 items of correspondence from members of the public received in 2018 about flash glucose monitoring. This figure represents correspondence received by the Department\u2019s Ministerial correspondence unit only. The Department has not been able to identify any correspondence specifically from charities.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-26", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "192109"} , {"_value" : "192110"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-26T17:43:55.08Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Diabetes: Medical Equipment"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he plans to make flash glucose monitoring technology available to all patients with diabetes across clinical commissioning groups.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"} } , "tablingMemberConstituency" : {"_value" : "York Outer"} , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"} ], "uin" : "192108"} , {"_about" : "http://data.parliament.uk/resources/1008480", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1008480/answer", "answerText" : {"_value" : "

Following an announcement by NHS England on 14 November 2018, flash glucose monitoring systems will be made available on prescription for all patients with type 1 diabetes who meet National Health Service criteria from April 2019.<\/p>

<\/p>

No estimate has been made of the potential savings related to making flash glucose monitoring technology available to all patients with diabetes.<\/p>

<\/p>

A search of the Department\u2019s Ministerial correspondence database has identified 272 items of correspondence from members of the public received in 2018 about flash glucose monitoring. This figure represents correspondence received by the Department\u2019s Ministerial correspondence unit only. The Department has not been able to identify any correspondence specifically from charities.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-26", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "192108"} , {"_value" : "192110"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-26T17:43:55.127Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Diabetes: Medical Equipment"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the potential savings to the NHS of making flash glucose monitoring technology available to all patients with diabetes across NHS clinical commissioning groups.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"} } , "tablingMemberConstituency" : {"_value" : "York Outer"} , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"} ], "uin" : "192109"} , {"_about" : "http://data.parliament.uk/resources/1007757", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007757/answer", "answerText" : {"_value" : "

The United Kingdom\u2019s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.<\/p>

<\/p>

Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including \u2018no deal\u2019. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks\u2019 additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.<\/p>

<\/p>

Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.<\/p>

<\/p>

We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T11:54:10.717Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Levetiracetam"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4648", "label" : {"_value" : "Biography information for Laura Smith"} } , "tablingMemberConstituency" : {"_value" : "Crewe and Nantwich"} , "tablingMemberPrinted" : [{"_value" : "Laura Smith"} ], "uin" : "191984"} , {"_about" : "http://data.parliament.uk/resources/1007762", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007762/answer", "answerText" : {"_value" : "

Dementia remains a key priority for the Government. We will implement the Prime Minister\u2019s Challenge on Dementia 2020 (published in February 2015) in full to make sure the lives of those with dementia are transformed by 2020.<\/p>

<\/p>

Working with our partners, we continue to make progress against the ambitions set in the March 2016 Implementation Plan which details how the commitments in the Challenge, across the four core themes of risk reduction, health and care, awareness and social action, and research will be met. This is reflected in the specific expectation set in the mandate to NHS England 2018/19 that two thirds of people living with dementia should receive a formal diagnosis. As of October 2018, the dementia diagnosis rate was 67.9%.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "answeringMemberConstituency" : {"_value" : "Gosport"} , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"} , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:37:58.543Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Dementia"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he has targets for improvements to care and services for people with dementia over the period of this Parliament.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"} } , "tablingMemberConstituency" : {"_value" : "East Londonderry"} , "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"} ], "uin" : "191881"} , {"_about" : "http://data.parliament.uk/resources/1007767", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007767/answer", "answerText" : {"_value" : "

The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).<\/p>

<\/p>

NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.<\/p>

<\/p>

NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE\u2019s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T15:13:09.58Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nusinersen"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4249", "label" : {"_value" : "Biography information for Anne Marie Morris"} } , "tablingMemberConstituency" : {"_value" : "Newton Abbot"} , "tablingMemberPrinted" : [{"_value" : "Anne Marie Morris"} ], "uin" : "191928"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpCreated=2018-11-16T15%3A26%3A07.223Z&answeringDeptId=17", "page" : 0, "startIndex" : 1, "totalResults" : 30203, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }